Skip to main content
Clinical Trials/NCT01913392
NCT01913392
Completed
Not Applicable

Prospective, Clinical Study of the Effect of Bariatric Surgery, Laparoscopic Sleeve Gastrectomy, on the Pharmacokinetics of Immunosuppressive Drugs in the Morbidly Obese, Kidney Transplant Candidate

Maisonneuve-Rosemont Hospital1 site in 1 country15 target enrollmentJuly 18, 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obesity, Morbid
Sponsor
Maisonneuve-Rosemont Hospital
Enrollment
15
Locations
1
Primary Endpoint
changes in the pharmacokinetics of oral immunosuppressive medications due to bariatric surgery, comparing pre-bariatric surgery to 12 months post-operative
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

A prospective clinical trial will study the effects of laparoscopic sleeve gastrectomy in the potential renal transplant candidate who is denied acceptance due mainly to the morbid obesity.

Detailed Description

The remaining factor in determining the effectiveness of bariatric surgery in the transplant population will be to study the effect on the pharmacokinetics of immunosuppressive medication, height, weight, BMI, abdominal circumference, blood pressure, Hba1c , average daily insulin requirements, lipid profile, TSH, 24h urine creatinine clearance and the SF-36 Quality of life questionnaire.

Registry
clinicaltrials.gov
Start Date
July 18, 2013
End Date
May 2018
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Gabriel Chan, Md

Transplant and general surgeon

Maisonneuve-Rosemont Hospital

Eligibility Criteria

Inclusion Criteria

  • adult (\>18 years)
  • stage IV and V chronic renal disease (glomerular filtration rate \< 30 ml/min,
  • body mass index (BMI) of greater than 40 kg/m2 or \> 35 with at least one co-morbidity such as hypertension, dyslipidemia or diabetes

Exclusion Criteria

  • medically unfit for surgical intervention
  • previous gastric or intestinal surgery
  • active gastric disease
  • pregnancy or lactation
  • known intolerance to tacrolimus or mycophenolic acid
  • awaiting potential multi-organ transplantation
  • active infection

Outcomes

Primary Outcomes

changes in the pharmacokinetics of oral immunosuppressive medications due to bariatric surgery, comparing pre-bariatric surgery to 12 months post-operative

Time Frame: pre-bariatric surgery and 1 year after surgery

Tacrolimus and Mycophenolate AUC 0-24h

degree of weight loss achieved after bariatric surgery in the chronic renal failure patient.

Time Frame: baseline and every 3 months

weight, BMI and abdominal circumference measures

Evaluate the change in general quality of life score, SF-36

Time Frame: Baseline and 1 year after bariatric surgery

comparison of the SF score between Baseline and month 3, Baseline and month 6 and Baseline and month 12

Secondary Outcomes

  • evaluate changes to residual renal function in the pre-dialysis renal transplant candidate(at baseline versus month 12 post-bariatric surgery)
  • the incidence of complications post-bariatric surgery will be evaluated(1, 6 and 12 months post-bariatric surgery)
  • evaluate the change in the number and dose of medications required to treat co-morbidities including, hypertension, hyperlipidemia and diabetes mellitus(baseline and 12 month post-bariatric surgery)

Study Sites (1)

Loading locations...

Similar Trials